STAT Plus: Pharmalittle: Drug pricing overhaul appears less likely; FDA to review drug given accelerated approval
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation — our choice today is hot-buttered rum. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …
President Donald Trump is turning up the heat on his own party over drug pricing, pressing Republicans for an ambitious solution aimed at slashing costs and taking control of a health care issue key to his 2020 reelection, Politico says. But the effort is already running into a familiar problem: Republicans on Capitol Hill have little idea what exactly the president wants, and where to start. Republican lawmakers are struggling to keep up with the evolving — and often contradictory — positions staked out by the Trump administration.
